| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
April 30, |
|
|
For the Six Months Ended
April 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Net loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
(1,879 |
) |
|
$ |
(1,713 |
) |
|
$ |
(3,897 |
) |
|
$ |
(3,469 |
) |
| CAR-T Therapeutics |
|
|
(925 |
) |
|
|
(1,444 |
) |
|
|
(2,101 |
) |
|
|
(2,970 |
) |
| Other |
|
|
(9 |
) |
|
|
(23 |
) |
|
|
(28 |
) |
|
|
(31 |
) |
| Total |
|
$ |
(2,813 |
) |
|
$ |
(3,180 |
) |
|
$ |
(6,026 |
) |
|
$ |
(6,470 |
) |
| Net loss |
|
$ |
(2,813 |
) |
|
$ |
(3,180 |
) |
|
$ |
(6,026 |
) |
|
$ |
(6,470 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,003 |
|
|
$ |
3,467 |
|
|
$ |
6,389 |
|
|
$ |
7,076 |
|
| Less non-cash stock-based compensation |
|
|
(988 |
) |
|
|
(1,260 |
) |
|
|
(2,043 |
) |
|
|
(2,520 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,015 |
|
|
$ |
2,207 |
|
|
$ |
4,346 |
|
|
$ |
4,556 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
1,364 |
|
|
$ |
1,160 |
|
|
$ |
2,831 |
|
|
$ |
2,373 |
|
| CAR-T Therapeutics |
|
|
643 |
|
|
|
1,026 |
|
|
|
1,491 |
|
|
|
2,154 |
|
| Other |
|
|
8 |
|
|
|
21 |
|
|
|
24 |
|
|
|
29 |
|
| Total |
|
$ |
2,015 |
|
|
$ |
2,207 |
|
|
$ |
4,346 |
|
|
$ |
4,556 |
|
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,015 |
|
|
$ |
2,207 |
|
|
$ |
4,346 |
|
|
$ |
4,556 |
|
| |
|
April 30,
2025 |
|
|
October 31,
2024 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
11,446 |
|
|
$ |
12,917 |
|
| CAR-T Therapeutics |
|
|
5,433 |
|
|
|
8,535 |
|
| Other |
|
|
98 |
|
|
|
139 |
|
| Total |
|
$ |
16,977 |
|
|
$ |
21,591 |
|
| Total assets |
|
$ |
16,977 |
|
|
$ |
21,591 |
|
|